Pain clinics and pain units see patients at a specific point in their journey: they have seen several doctors, tried several things, and many have been told there is nothing more to be done. It is a context where any new proposal is met with hope — which is why it deserves the greatest care.
There is one distinction that decides almost everything that follows.
Acute and chronic pain are not the same conversation
Acute pain — of a procedure, a dressing change, a cannulation — is an event with a beginning and an end. Attention is a limited resource, and occupying it for those minutes has documented effect. This is where the most consistent evidence for virtual reality in health sits, and we develop it in pain management.
Chronic pain is something else. It is not acute pain that went on: it involves changes in pain processing, fear of movement, avoidance, disturbed sleep, mood, and a life gradually organised around the pain. Distracting someone for twenty minutes changes none of that.
Confusing the two is this sector's most common commercial error. The evidence for the first is used to sell into the second.
What a pain unit does, and where this might fit
A modern approach to chronic pain is multimodal: medication where indicated, exercise and reactivation of movement, a psychological component, pain education, sleep hygiene, and work on function rather than on intensity.
If virtual reality has a place, it is inside one of those components, not alongside them:
- During procedures done in the unit — injections, blocks, device placement. This is acute pain, and the good evidence applies.
- In supporting movement, for those avoiding it out of fear. The obstacle is frequently fear rather than capacity. A necessary note: that corresponds to the RVer Motion module, which is in development and not covered by the Class I medical device registration.
- As a relaxation component, inside a plan that already exists and run by whoever runs it.
Where the evidence is weak, and it should be said
In chronic pain, existing studies are mostly small, short and heterogeneous: different populations, different protocols, different outcomes. Several show improvements during the session that do not persist afterwards. That is an interesting signal, and not the same thing as lasting clinical effect.
We gathered what exists in the study library, where pain is among the best represented themes — and reading the list is more useful than any claim from us. Where the evidence does not support something, we say so there too, as we did in what cannot be proven.
What we do not claim, and will not: that RVer reduces chronic pain, that it reduces analgesic use, or that it replaces any component of a pain plan. The base product is a Class I medical device used as a non-pharmacological complement, under supervision. It does not assess pain, measure it or classify it.
The specific risk in this population
Worth naming, because it differs from other settings: these people have been disappointed several times already. A proposal presented with too much enthusiasm, which then does not deliver, is not neutral — it reinforces the idea that nothing works, and it costs credibility to whoever presented it, which is the team and not the supplier.
So if you are going to test, it is worth telling the patient exactly what to expect: "this may make this procedure easier" is one thing; "this may help with your pain" is another, and the second does not hold.
What a unit can test without promising anything
- One concrete procedure already done in the unit, compared with usual care.
- Refusals and interruptions, where problems appear first.
- Function, not intensity. What the person can do is more informative than a number on a scale, and it is what the unit already tends to measure.
- Three months, not three weeks.
In short
- The good evidence is in acute pain, and it is frequently used to sell into chronic pain.
- Chronic pain is multimodal — if this enters, it enters inside a component.
- In chronic pain the studies are small and short, with effects that often do not persist.
- We claim no reduction in pain or in analgesics.
- Over-promising to this population costs the team credibility, not the supplier.